Multiple Myeloma Clinical Trial

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

Summary

The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Clinical Diagnosis of MM requiring treatment
Refractory or Relapsed Disease
At least one prior treatment regimen
Male or Female
>18 years of age

Exclusion Criteria:

Prior Allogeneic bone marrow transplant (prior autologous transplant allowed)
Intracranial disease or epidural disease
Clinically significant cardiac dysfunction or other significant organ dysfunction

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

33

Study ID:

NCT00231166

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102
Boston Massachusetts, 02115, United States
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer
New York New York, 10011, United States
Oregon Health Sciences University
Portland Oregon, 97239, United States
University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102
Philadelphia Pennsylvania, 19104, United States
Fred Hutchinson Cancer Research Center Dept. of FHCRC
Seattle Washington, 98109, United States
Novartis Investigative Site
Herston Queensland, 4029, Australia
Novartis Investigative Site
Prahran Victoria, 3181, Australia

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

33

Study ID:

NCT00231166

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider